- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01334138
Effect of Dietary Sodium Intake on Blood Pressure in Hypertensive Patients in Primary Care
There is strong evidence that our current consumption of salt is the major factor increasing blood pressure (BP). The current salt intake in most countries in the world is 9 to 12 grams per day (g/d), whil the World Health Organization's recommendation is < 5 g/d.
The aims of the present study is to determine if the overconsumption of salt influences the bp in patients with uncontrolled hypertension or frequently elevated bp.
Each study subject will complete questionnaires, and their usual dietary salt intake is estimated from food composition on 3 completed food diaries. This is also compared with a 24-hour urine sample collection.
Based on these results, the study subject receives personal advice to decrease sodium consumption and will change the diet for at least 28 days. During this diet, bp will be measured and food diaries will be completed. After the intervention, a questionnaire and a 24-hour urine sample collection will be collected.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Ghent, Belgium, 9000
- University Ghent
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adults, 50 years of age or older with changing blood pressure (bp) with or without drugs and patients with uncontrolled bp despite drugs
- An average systolic bp on 2 of the 3 previous visits of 140 mm Hg or more (130 mm Hg for diabetics) and an average diastolic bp of 80 to 100 mm Hg.
- Blood analysis (fasting glycaemia, creatinin, total cholesterol, high- density lipoprotein cholesterol) in the last 6 months
At least 3 criteria of the following:
- using table salt
- 2-3/weeks consumption of prepared meals (butchery, warehouse...)
- 2-3/weeks consumption of effervescent tablet
- Daily consumption of cheese/cold cuts
- Daily consumption of salted butter/margarine
- 2-3/weeks consumption of smoked fish/meat
- 2-3/weeks consumption of bouillon cube-soup (self-made or preserved)
- 2-3/weeks consumption of cookies
- 2-3/weeks consumption of vegetables preserved in jars
- 2-3/weeks consumption of vegetable juice
- 2-3/weeks consumption of snacks (chips, cheese, nuts...)
Exclusion Criteria:
- heart failure
- renal insufficiency
- secondary hypertension
- isolated systolic/diastolic hypertension
- bp difference of more than 10 mm Hg between left and right arm
- lactation or pregnancy
- active malignancy
- an active 'low in salt' diet
- changing the use of antihypertensive drugs or other medication that would affect bp for the last 4 weeks
- impaired cognitive functioning$
- planning a smoke cessation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 4-week diet, low in sodium
The study subjects go on a 4-week diet, low in sodium.
|
Study subjects receive personal advice to decrease sodium consumption and will change his diet for 28 days. Follow up is performed by measuring blood pressure, a 24-hour urine sample collection, diaries and questionnaires. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Measurement of blood pressure after a 4-week diet, low in sodium.
Time Frame: after 4 weeks
|
after 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Life style change after a 4-week diet, low in sodium.
Time Frame: after 4 weeks
|
after 4 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stefaan Dehenauw, Ph.D, Professor, University Ghent
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2010/233
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arterial Hypertension
-
VIVUS LLCNot yet recruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAH
-
Rutgers, The State University of New JerseyRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension of Congenital Heart Disease | Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) | Pulmonary Arterial and Chronic Thromboembolic... and other conditionsUnited States
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyNot yet recruiting
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganNot yet recruitingPulmonary Arterial Hypertension (PAH)United States
-
University of Sao Paulo General HospitalRecruitingPulmonary Arterial Hypertension (PAH)Brazil
-
University Hospital, BrestNot yet recruitingPulmonary Arterial Hypertension (PAH)France
-
Shanghai Zhongshan HospitalNot yet recruitingPulmonary Arterial Hypertension (PAH)
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
Regeneron PharmaceuticalsRecruitingPulmonary Arterial Hypertension (PAH)United States, United Kingdom, Latvia, South Korea
-
University of Sao Paulo General HospitalNot yet recruitingPulmonary Arterial Hypertension (PAH)Brazil
Clinical Trials on A 4-week diet, low in sodium.
-
Burke Rehabilitation HospitalCompletedStroke | Ischemic StrokeUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Ospedali Riuniti di FoggiaCompleted
-
University of DelawareCompleted
-
Regional Hospital HolstebroCompletedHealthy HumansDenmark
-
Mondelēz International, Inc.Centre de Recherche en Nutrition Humaine Rhone-Alpe; Biofortis Mérieux NutriSciencesCompleted
-
Wolfson Medical CenterUnknown
-
University of Sao PauloCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Fundação de Apoio...CompletedHeart Failure; With Decompensation | Heart Failure,CongestiveBrazil
-
Maastricht University Medical CenterCompletedHypertension | Metabolic Syndrome | Insulin Resistance | Abdominal Obesity | Sodium-sensitivityNetherlands
-
DongGuk UniversityBoryung Pharmaceutical Co., LtdCompletedHypertensionKorea, Republic of
-
University of VirginiaNational Heart, Lung, and Blood Institute (NHLBI)Unknown